Hypothesis

Senescent cells act not only as inflammatory signal hubs but also as metabolic gatekeepers that supply neighboring stem and progenitor cells with essential redox‑balancing metabolites via the SASP. Acute clearance of these cells disrupts this metabolic support, leading to increased oxidative DNA damage and a rise in mutagenesis that can outweigh the benefits of reduced SASP‑driven inflammation.

Mechanistic Basis

Recent work shows senescent fibroblasts in wound healing secrete PDGF‑AA to drive fibroblast differentiation[1]. Beyond growth factors, senescent cells release metabolites such as kynurenine, NAD⁺ precursors, and reduced glutathione through exosomes and soluble factors[2]. These molecules sustain NADPH‑dependent antioxidant systems in adjacent epithelial progenitors, keeping ROS levels low enough to prevent DNA lesions while proliferation is paused. In salamanders, rapid macrophage‑dependent clearance of senescent cells coincides with a transient surge in metabolite transfer that fuels blastema formation without accumulating damage[3]. When immune surveillance falters with age, metabolite secretion wanes, ROS rise, and the tissue suffers from both inflammatory SASP and oxidative stress[4].

We propose that the protective metabolite flux is the hidden "deal" senescent cells broker. Removing the cells with senolytics ends the inflammatory negotiation but also cuts off the metabolic supply line, shifting the balance toward genomic instability.

Predictions & Experimental Design

1. Metabolite depletion: In young mouse skin, inducible ablation of p16^INK4a^‑positive senescent cells will cause a measurable drop in tissue NAD⁺/NADH ratio and glutathione levels within 48 h post‑clearance, detectable by LC‑MS/MS.
2. Oxidative DNA damage: The same mice will show a significant increase in 8‑oxo‑guanine staining in keratinocyte progenitors compared with controls, quantifiable by immunofluorescence and flow cytometry.
3. Mutagenesis read‑out: Using a GFP‑based frameshift reporter integrated into the epidermal basal layer, we expect a 2‑fold rise in mutant colonies after senolytic treatment, indicating heightened mutagenesis.
4. Rescue test: Exogenous delivery of senescent‑cell‑derived exosomes or NAD⁺ precursors (e.g., nicotinamide riboside) should normalize ROS levels and prevent the mutation surge despite senescent cell removal.
5. Long‑term outcome: Mice receiving senolytics plus metabolite rescue will exhibit improved wound‑healing kinetics without the increase in hyperplastic lesions seen with senolytics alone.

All predictions are falsifiable: if metabolite levels stay stable, ROS does not rise, or mutagenesis does not increase after senescent cell clearance, the hypothesis fails.

Potential Implications

This reframes senolytics from a simple "remove the bad" strategy to a nuanced intervention that must preserve or replace the metabolic niche senescent cells provide. It suggests combinatorial approaches—senolytics paired with metabolite supplementation—could achieve cancer‑protective benefits without unleashing genomic chaos. Testing this in regenerative contexts (e.g., limb bud models) may also reveal why some vertebrates tolerate transient senescence while others suffer accumulation‑driven decline.